whitepaper

Application note: A novel solution to expedite antibody discovery

Posted: 29 November 2018 | | No comments yet

With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.

Please complete the form below in order to download this application note:












*

*

*

*

*

*

*

*

 


This content is provided to you for free thanks to the kind support of our sponsors: IntelliCyt

Send this to a friend